Adjuvant chemotherapy with gemcitabine and long term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA 2013; 310: 1473-1481.

Published: 14th April 2014

Authors: Oettle H, Neuhaus P, Hochhaus A, Hartmann JT, Gellert K, Ridwelski K et al. et al.

Conclusion

This study included 368 patients followed for a median of 136 months. Adjuvant gemcitabine for six months improved median disease-free survival (13.4 versus 6.7 months, P<0.001) and overall 5-year survival: 20.7 versus 10.4 per cent, P=0.01.

Pubmed Link

Your comments

0 Comments